Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Aclaris Therapeutics (NASDAQ:ACRS) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03), Zacks reports. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%. The company had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million.

Aclaris Therapeutics Price Performance

Shares of ACRS stock traded up $0.19 during trading hours on Thursday, hitting $2.45. 1,005,888 shares of the company’s stock were exchanged, compared to its average volume of 998,016. Aclaris Therapeutics has a 52 week low of $0.59 and a 52 week high of $5.61. The stock has a market cap of $174.80 million, a price-to-earnings ratio of -2.99 and a beta of 0.10. The stock’s 50-day moving average is $1.32 and its 200-day moving average is $1.24.

Analyst Ratings Changes

Several equities research analysts have recently commented on ACRS shares. HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th. StockNews.com upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 25th. Seven equities research analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.